E-FORCSE Home Page
Physicians that are not treating patients for chronic nonmalignant pain are not required to register as controlled substance prescribers.
The Department has received numerous calls in recent weeks from physicians expressing concerns that some pharmacists are not filling controlled substance prescriptions if the physician is not listed as a controlled substance prescriber on the practitioner profile on Department of Health’s website. While there may be many reasons a pharmacist may decide in his or her professional judgment not to fill a prescription, the Department wants to ensure that any confusion concerning the physician registration requirements is addressed.
The lack of a designation on the physician profile concerning controlled substances does not necessarily mean that the physician cannot prescribe controlled substances. Section 456.44, F.S. requires a physician licensed under chapter 458, chapter 459, chapter 461, or chapter 466 who prescribes controlled substances listed in Schedule II, Schedule III, or Schedule IV for the treatment of chronic nonmalignant pain, to designate himself or herself as a controlled substance prescribing practitioner on the physician’s practitioner profile. This requirement is only applicable to those physicians that are treating patients for chronic nonmalignant pain. Therefore, physicians that are not treating patients for chronic nonmalignant pain are not required to register and may continue prescribing controlled substances for other diagnoses.
Welcome to E-FORCSE®, Florida's Prescription Drug Monitoring Program
The Florida Prescription Drug Monitoring Program, known as E-FORCSE® (Electronic-Florida Online Reporting of Controlled Substance Evaluation Program), was created by the 2009 Florida Legislature in an initiative to encourage safer prescribing of controlled substances and to reduce drug abuse and diversion within the state of Florida.
E-FORCSE® has selected Health Information Designs, LLC, to develop a database that collects and stores prescribing and dispensing data for controlled substances in Schedules II, III, and IV. The purpose of the PDMP is to provide the information that is collected in the database to health care practitioners to guide their decisions in prescribing and dispensing these highly abused prescription drugs.
Section 893.055, Florida Statutes, requires health care practitioners to report to the PDMP each time a controlled substance is dispensed to an individual. The information is reported through the electronic system as soon as possible but not more than 7 days after dispensing. This reporting timeframe ensures that health care practitioners have the most up-to-date information available.
E-FORCSE® complies with the Health Insurance Portability and Accountability Act (HIPAA) as it pertains to protected health information (PHI), electronic protected health information (EPHI), and all other relevant state and federal privacy and security laws and regulations. The information collected in the system will be used by the PDMP to encourage safer prescribing of controlled substances and to reduce drug abuse and diversion within the state of Florida.
Pharmacy & Dispensing Practitioner Controlled Substance Reporting Requirements:The Department of Health’s Prescription Drug Monitoring Program called E-FORCSE collects, maintains, and stores controlled substance prescription dispensing information in its database and makes the information available to health care practitioners and law enforcement and regulatory agencies during active investigations. Section 893.055, F.S., requires all practitioners who dispense controlled substances listed in schedules II, III, or IV, as defined in section 893.03, F.S., to report to E-FORCSE within 7 days each time a controlled substance is dispensed to an individual, unless it is one of the acts of dispensing or administering which are exempt from reporting under subsection 893.055(5), F.S. For more information visit, http://www.floridahealth.gov/statistics-and-data/e-forcse/.
Wholesale Distributor, Manufacturer or Repackager Controlled Substance Reporting Requirements:The Department of Business and Professional Regulation, Division of Drugs, Devices and Cosmetics Program, Controlled Substance Registry collects and stores controlled substance receipts and distributions in its registry. Section 499.0121(14), Florida Statutes (F.S.) requires each prescription drug wholesale distributor, whether in state or out-of-state, retail pharmacy drug wholesale distributor, manufacturer, or repackager that engages in the wholesale distribution of controlled substances to report receipts and distributions of controlled substances listed in Schedule II through V, as provided in s. 893.03, F.S., monthly by the 20th of the next month. For more information visit http://www.myfloridalicense.com/dbpr/ddc/CSR.html.
This project was supported by Grant No. 2009-PM-BX-4004 awarded by the Bureau of Justice Assistance, Office of Justice Program, U.S. Department of Justice.